Lofexidine: Opioid Withdrawal, Side Effects and Care After Detox

Lofexidine is a centrally acting alpha-adrenergic agonist used to manage opioid-withdrawal symptoms. Lucemyra is a US brand example. It may reduce the severity of symptoms but does not necessarily remove them all. Its use and availability should be checked against local product information rather than assumed from another country’s treatment website. [1]

Ask why lofexidine is being proposed and what the overall objective is. There is an important difference between helping someone through a withdrawal episode and providing ongoing treatment that reduces return to opioid use. The prescription should be connected to a continuing plan, with clear responsibility for symptoms, mental health concerns and the next stage of care.

During opioid withdrawal, the body’s stress-response activity can contribute to symptoms such as sweating, a pounding heart, restlessness and physical discomfort. Lofexidine acts on central alpha receptors and can reduce this overactivity. Its effects on blood pressure and heart rate are also important safety considerations. It does not act by replacing an opioid with another opioid. [1]

That difference in mechanism should not be treated as proof that it is always the best option. Ask how the clinician has considered alternatives and what would prompt a change in the plan. A person who remains unable to manage symptoms needs reassessment, not an instruction to take extra tablets or endure whatever happens because the medicine is non-opioid.

For opioid use disorder, detoxification alone leaves important risks unresolved. CDC recommends evidence-based medication treatment and warns that withdrawal without ongoing medication treatment is associated with increased return-to-use and overdose risks. Buprenorphine, methadone and naltrexone have different roles from a symptom-relieving medicine such as lofexidine. [2]

Before treatment begins, ask what will happen afterward. Will you be offered ongoing medication, psychological support or both? Who will provide the next appointment? What happens if craving returns before that visit? These questions should not be postponed until the last day of detox. The absence of acute withdrawal symptoms does not by itself mean that the longer-term condition no longer needs treatment.

A clinician needs to consider recent opioid exposure, other substances, medical conditions, pregnancy and previous withdrawal experience. The right setting cannot be determined from the name lofexidine alone. A medication that can be prescribed outside hospital in some circumstances is not evidence that every person can safely manage withdrawal at home.

Tell the team about alcohol or benzodiazepine dependence as well as opioids. Those withdrawal risks need separate assessment and should not be assumed to be covered by lofexidine. Ask what observations are required and whom to contact if symptoms worsen. Severe illness, confusion, a seizure, collapse or inability to stay safe warrants urgent medical care. This page does not establish that COGNIFUL can provide every form of medical detoxification.

Lofexidine can cause low blood pressure, dizziness or fainting, especially when standing. Dehydration and overheating can make these problems more likely. If you feel faint, sit or lie down and obtain advice, particularly if symptoms persist. A collapse or severe associated symptoms needs urgent assessment. Do not keep taking extra doses to manage withdrawal while ignoring increasing lightheadedness. [1]

Ask the prescriber what monitoring is needed and what to do before the next dose if symptoms occur. An individualized plan may include blood-pressure or pulse checks, but an internet threshold cannot replace the instructions for your circumstances. Explain whether you are able to drink normally or have vomiting or diarrhea. The team needs that information when judging medication safety.

Tell the clinician about long QT syndrome, irregular heartbeat, heart disease, previous stroke and kidney or liver problems. Low potassium or magnesium and other medicines can also be relevant to the risk assessment. Some people need additional monitoring or a different prescribing approach. Do not assume a medicine used briefly has no meaningful interaction or cardiac precautions. [1]

Bring the actual medication list, including methadone or other opioid treatment received recently, antidepressants, blood-pressure medicines and supplements. Ask who will review any test results and which symptoms should trigger urgent contact. Fainting or an irregular heartbeat should not automatically be attributed to anxiety or withdrawal without assessment.

Follow the prescribed tablet schedule and do not take more often than directed. The clinician may need to adjust or interrupt treatment in response to adverse effects. Do not copy a regimen from someone else or use this guide to choose a starting dose. Product instructions and clinical supervision should determine how the medicine is used. [1]

Ask for the plan in writing, including how to handle a missed dose and whom to call if it is unclear. Avoid doubling doses. If you cannot reliably follow the schedule because of illness, travel or symptoms, tell the service rather than compressing doses into a shorter period. Treatment should remain understandable when you are tired or uncomfortable, not depend on making complex decisions without support.

Dry mouth, sleep difficulties, drowsiness and ringing in the ears may occur. Dizziness and faintness deserve particular attention because they affect safety. Avoid driving or operating equipment when impaired. Describe persistent effects to the clinician and distinguish them from the withdrawal symptoms being treated where possible, without assuming you must identify the cause yourself. [1]

Useful observations include when symptoms began, whether they follow a dose and what ordinary activities they prevent. Ask whether a change needs prompt assessment or can be discussed at the scheduled review. Do not add sedating remedies or alcohol to manage sleep. The rest of the medication plan needs to be considered before another product is introduced.

Lofexidine is not a routine antidepressant, antipsychotic or treatment for a primary anxiety disorder. Anxiety, low mood, trauma symptoms and insomnia during withdrawal can overlap with pre-existing mental health problems. They should be reviewed rather than assumed to have a single cause. A reduction in sweating or a slower pulse does not establish that emotional distress has been adequately treated.

Tell the team about prior depression, bipolar episodes, psychosis, self-harm and current thoughts of suicide. Immediate danger requires emergency help rather than waiting for the withdrawal course to finish. Ask who will provide mental health assessment and continuing support. The co-occurring-needs overview explains the wider need for coordinated care, not an indication for lofexidine itself.

After opioid abstinence, tolerance may be lower. Returning to an amount previously used can therefore cause overdose. Lofexidine does not block opioids or provide overdose protection. Discuss naloxone access and a rescue plan as part of withdrawal care, including what a trusted person should do in an emergency. [1] [3]

If someone cannot be awakened or has slow or abnormal breathing after possible opioid use, call emergency services and use available naloxone according to its instructions. Follow dispatcher guidance and remain with the person. Do not assume completing detox makes a return to use less dangerous. The next stage of treatment should address this risk explicitly.

Stopping lofexidine suddenly can cause a rise in blood pressure and symptoms such as anxiety, sweating or sleep disturbance. The prescriber should direct the reduction at the end of the course. Do not confuse a short intended treatment period with permission to stop however you choose. The plan should cover stopping the withdrawal-support medicine as well as stopping the original opioid. [1]

Ask what to do if symptoms appear during the reduction and whether they may relate to lofexidine, opioid withdrawal or another problem. Keep a simple timeline of medication changes, but do not let that delay assessment of severe symptoms. There is no universal taper in this guide. Your clinician must consider the course you actually took and your current physical condition.

Before leaving a service, confirm the next point of contact, medications and any appointments. Ask whether an evidence-based ongoing opioid treatment has been offered and how to access it if the first plan is not working. A return to use should trigger reassessment and support rather than exclusion from care. Continuing treatment may be needed even when the withdrawal course has been completed. [2]

Bring questions about pain, sleep, mood, work and family life into the plan. These do not disappear when a symptom score improves. Make sure the handover states which medicines have ended, which continue and who can advise about each. Our medication-review checklist can help organize that discussion.

Is lofexidine an opioid?

No. It acts through alpha-adrenergic mechanisms, but still has important blood-pressure and other precautions. [1]

Does it replace long-term opioid-use-disorder treatment?

No. Relief of withdrawal symptoms and continuing addiction treatment have different purposes. Discuss the ongoing plan before the short withdrawal course ends.

Can I stop as soon as I feel better?

Follow the prescriber’s stopping instructions. Abrupt discontinuation can create additional symptoms and blood-pressure problems.

1. MedlinePlus: Lofexidine.
2. CDC: Opioid use disorder treatment.
3. CDC: Naloxone and overdose response.

Educational information only. Your local product leaflet and clinical team determine individual care. Inclusion is not a prescribing or detox-service promise. Return to the medication library.